News

Almost half of new HIV diagnoses in the US are African-American patients. Where is the root of the issue?

The addition of guanfacine to a psychostimulant improved executive function in children with ADHD.

FDA Commissioner Scott Gottlieb released a statement deliniating the agency's concerns about the plant substance and its health consequences.

The United States and India are joining forces to engage the rare disease community in honoring International Rare Disease Day and the millions of patients around the world.

Children’s Hospital Los Angeles (CHLA) has announced that it will be participating in a new clinical trial with the hopes of improving quality of life (QOL) outcomes for children with hypoplastic left heart syndrome (HLHS), a congenital heart defect in which the left ventricle is severely underdeveloped.

The 50-mg dose showed that 19.2% of patients were free of pain after 2 hours while the 100-mg dose resulted in 21.2% of pain-free patients.

Complementary and alternative medicine can decrease the rate of antimicrobial resistance and reduce treatment costs.

The FDA has granted Breakthrough Therapy Designation to Zogenix’s drug ZX008, a therapy intended to treat seizures associated with Dravet syndrome.

The Embrace smartwatch allows patients with epilepsy to monitor for seizure activity without wearing an EEG

The research has the potential to add a less expensive adjunctive therapy to improve current HCV regimens.

Inhaled anticholinergic bronchodilator tiotropium as an add-on therapy has the potential to reduce exacerbations.

Frequent substance abuse in young adults with childhood ADHD is accompanied by greater initial exposure at a young age and slightly faster progression.

The use of SD OCT could help determine the presence of submacular fluid, the absence of hyper-reflective foci, and a continuous inner segment-outer segment.

Implementing a standardized C. difficile screening protocol was associated with a significant decrease in the rate of HO-CDI among BMT patients

The infographic on this page will take you from the inception of Rare Disease Day to present day.

The U.S. FDA has granted Capricor Therapeutics RMAT designation for its lead investigational cell therapy for the treatment of Duchenne muscular dystrophy, CAP-1002.

Jupiter Orphan Therapeutics announced this morning that it intends to submit an Investigational New Drug application to the U.S. FDA for Jotrol in MPS I, among other indications, within the next few weeks.

Fibrocell Science announced the submission of an Investigational New Drug Application with the U.S. FDA for FCX-013, a gene therapy candidate for the treatment of moderate to severe localized scleroderma.

The approval has expanded ferumoxytol's indication to include all adults with iron deficiency anemia.

Combination ART has dramatically improved survival rates among those living with HIV and is a mainstay of HIV prevention.

Physician suicide is a taboo topic—and despite high rates of depression and PTSD among doctors, little help exists for those at risk.

A newly developed Environmental Scoring System proves useful in disparate home-based asthma intervention programs.

Puneet Gandotra, MD, spoke about the needs of interventional cardiology.

Vijay Singh, MD, a cardiothoracic surgeon with Northwell Health, discussed the ongoing debate surrounding the use of robotics in surgery, and where the two sides stand.

Researchers used molecular genetic and biochemical approaches to understand the capacity of a virus to create and use pores punched through the cell membrane.

Puneet Gandotra, MD, spoke about the fears and challenges that interventional cardiologists have and face every day just doing their jobs.

The director of the Ara Parseghian Medical Research Fund promoted the organization’s new initiatives to raise money for NPC1 research during an address to Notre Dame’s student senate this week.

This is the first gram-negative antibiotic approved in the US in over 15 years to treat HABP, VABP.

Yesterday, nonprofit organization BioPontis Alliance and Massachusetts General Hospital, the largest hospital-based research program in the United States, announced an agreement to target new treatments for Huntington’s disease.